GlassScriptPhysician profile
Cami Peterson
NPI 1932986734
$1,163.57
in general payments reported to CMS, 2019-2025
24 companies · $653 in 2025
The $653 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $511 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $155.50 | 2024 | Evenity, Tavneos |
| Otsuka America Pharmaceutical, INC. | $140.90 | 2025 | Rexulti |
| Abbvie INC. | $101.47 | 2025 | |
| Glaxosmithkline, LLC. | $95.66 | 2024-2025 | Trelegy Ellipta |
| Corcept Therapeutics | $59.40 | 2024 | Korlym |
| Lilly USA, LLC | $57.15 | 2024 | Mounjaro, Zepbound |
| Ironshore Pharmaceuticals INC. | $55.38 | 2024 | |
| Lundbeck LLC | $49.01 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.41 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $45.25 | 2024-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $43.42 | 2024-2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $41.63 | 2024-2025 | |
| Pfizer INC. | $37.71 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $30.77 | 2024-2025 | Farxiga |
| Averitas Pharma INC. | $29.53 | 2025 | Qutenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $26.22 | 2025 | Rotateq, Capvaxive, M-M-R II |
| Shield Therapeutics INC | $23.50 | 2025 | |
| Organon LLC | $22.97 | 2024-2025 | Nexplanon |
| Cranial Technologies, INC | $18.83 | 2025 | Doc Band |
| Neurocrine Biosciences, INC. | $18.17 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $17.48 | 2024 | |
| Agios Pharmaceuticals, INC. | $17.30 | 2024 | Pyrukynd |
| Bayer Healthcare Pharmaceuticals INC. | $14.17 | 2025 | |
| Novo Nordisk INC | $13.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cami Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.